Research Use Only
This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.
Semaglutide
Metabolic & Weight LossFDA ApprovedAlso known as: Sema, RC-1S, PEP-1S, GLP-1, GLP-1 Agonist
Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1. FDA-approved as Ozempic (type 2 diabetes, 2017) and Wegovy (chronic weight management, 2021).
Overview
Key Takeaways
- →Weight loss
- →Type 2 diabetes management
- →Cardiovascular risk reduction
- →Half-life: ~7 days (enabling once-weekly dosing)
At A Glance
Semaglutide binds and activates GLP-1 receptors in the pancreatic beta cells, potentiating glucose-dependent insulin secretion while suppressing glucagon. In the hypothalamus and brainstem, GLP-1R activation reduces appetite and food intake by modulating energy homeostasis circuits. Gastric emptying is delayed, extending satiety signals. The albumin-binding fatty acid side chain provides extended half-life of approximately 7 days, enabling once-weekly dosing.
Semaglutide binds and activates GLP-1 receptors in the pancreatic beta cells, potentiating glucose-dependent insulin secretion while suppressing glucagon. In the hypothalamus and brainstem, GLP-1R activation reduces appetite and food intake by modulating energy homeostasis circuits. Gastric emptying is delayed, extending satiety signals. The albumin-binding fatty acid side chain provides extended half-life of approximately 7 days, enabling once-weekly dosing.
Overview
Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1. FDA-approved as Ozempic (type 2 diabetes, 2017) and Wegovy (chronic weight management, 2021). The STEP trials demonstrated 15–17% mean body weight reduction at 68 weeks with 2.4 mg weekly dosing, establishing it as the leading pharmaceutical treatment for obesity.
Potential Benefits
Potential Research Fields
Chemical Information
IUPAC Name
N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetamido]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37)-peptide
CAS Number
910463-68-2
Molecular Formula
C187H291N45O59
Molecular Mass
4113.58 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Create a free account to:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
Join 2,800+ researchers
Research
Unlock Research Data
Create a free account to:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
Join 2,800+ researchers
Interactions
Interaction Matrix
Contraindications
Personal or family history of medullary thyroid carcinoma (MTC). Multiple endocrine neoplasia syndrome type 2 (MEN 2). History of pancreatitis. Severe gastrointestinal disease. Type 1 diabetes. Pregnancy or breastfeeding. Eating disorders (may exacerbate restriction).
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$59.99
up to $174.99
$5.8330
4
5
vial
Price History
2 data pointsRelated Compounds
View AllAOD-9604
Metabolic & Weight Loss
AOD-9604 is a modified 16-amino acid fragment of the C-terminal region of human growth hormone (residues 176-191) with an additional tyrosine at the N-terminus and a disulfide bond.
Cagrilintide
Metabolic & Weight Loss
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk.
HGH Fragment 176-191
Metabolic & Weight Loss
HGH Fragment 176-191 is a stabilized peptide fragment of the C-terminus of human growth hormone, corresponding to amino acids 176–191 with a tyrosine addition at the N-terminus.
Retatrutide
Metabolic & Weight Loss
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously.
Tirzepatide
Metabolic & Weight Loss
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023).
View Full Dosage Guide →
Protocols, calculator & safety for Semaglutide
Research Score
3077 PubMed studies
Quality Indicators
Data Completeness
100%COA Verification
10
Verified COAs
2
Vendors w/ COA
High verification rate (83%)
Latest test: 3/1/2026
Research Credibility
Well-researched compound
Quick Facts
Half-Life
~7 days (enabling once-weekly dosing)
Molecular Weight
4113.58 g/mol
Administration
Subcutaneous, Oral
CAS Number
910463-68-2
Trial Phase
FDA Approved
Safety Profile
Moderate RiskCommon Side Effects
- • Nausea
- • Vomiting
- • Diarrhea
- • Constipation
- • Abdominal pain
Stop Use If
- Medullary thyroid carcinoma history
- MEN2 syndrome
- Pancreatitis signs
- Allergic reaction
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Semaglutide used for in research?
Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1. FDA-approved as Ozempic (type 2 diabetes, 2017) and Wegovy (chronic weight management, 2021). The STEP trials demonstrated 15–17% mean body weight reduction at 68 weeks with 2.4 mg weekly dosing, establishing it as the leading pharmaceutical treatment for obesity.
What forms does Semaglutide come in?
Semaglutide is available in vial form.
How much does Semaglutide cost?
Prices start at $59.99 across 4 verified vendors.
How do I compare Semaglutide vendors?
Compare prices, payment methods, shipping, and COA scores across 4 vendors.
Research Tools
Related Compounds
View AllAOD-9604
Metabolic & Weight Loss
AOD-9604 is a modified 16-amino acid fragment of the C-terminal region of human growth hormone (residues 176-191) with an additional tyrosine at the N-terminus and a disulfide bond.
Cagrilintide
Metabolic & Weight Loss
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk.
HGH Fragment 176-191
Metabolic & Weight Loss
HGH Fragment 176-191 is a stabilized peptide fragment of the C-terminus of human growth hormone, corresponding to amino acids 176–191 with a tyrosine addition at the N-terminus.
Retatrutide
Metabolic & Weight Loss
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously.
Tirzepatide
Metabolic & Weight Loss
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023).